Plasma concentrations of matrix metalloproteinase-2, tissue inhibitor of metalloproteinase-1 and osteopontin reflect severity of heart failure in DOCA-salt hypertensive rat

Biomarkers

Volumn 13, Issue 3, 2008, Pages 270-281

  Kramer, Frank ^a   Sandner, Peter ^a   Klein, Martina ^a   Krahn, Thomas ^a  

^a BAYER PHARMA AG   (Germany)

Author keywords

Cardiac remodelling; DOCA salt hypertensive rat; MMP 2; OPN; Spironolactone; TIMP 1

Indexed keywords

ATRIAL NATRIURETIC FACTOR; DEOXYCORTICOSTERONE ACETATE; GELATINASE A; NATRIURETIC PEPTIDE RECEPTOR B; OSTEOPONTIN; SPIRONOLACTONE; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE MONITORING; BLOOD SAMPLING; BODY WEIGHT; CONTROLLED STUDY; DISEASE SEVERITY; DRUG RESPONSE; HEART FAILURE; HEART HEMODYNAMICS; HEART LEFT VENTRICLE CONTRACTILITY; HEART MUSCLE FIBROSIS; HEART WEIGHT; MALE; NONHUMAN; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; RAT;

ANIMALS; BIOLOGICAL MARKERS; BLOOD PRESSURE; DESOXYCORTICOSTERONE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HEART FAILURE; HEART VENTRICLES; MALE; MATRIX METALLOPROTEINASE 2; MYOCARDIAL CONTRACTION; OSTEOPONTIN; RATS; RATS, SPRAGUE-DAWLEY; SALTS; SPIRONOLACTONE; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

ANIMALIA; RATTUS;

EID: 42349093037     PISSN: 1354750X     EISSN: 13665804     Source Type: Journal    
DOI: 10.1080/13547500801903123     Document Type: Article

References (40)

1. Ahmed, SH, Clark, LL, Pennington, WR, Webb, CS, Bonnema, DD, Leonardi, AH, McClure, CD, Spinale, FG and Zile, MR. (2006) Matrix metalloproteinases/tissue inhibitors of metalloproteinases: Relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease. Circulation, 113, pp. 2089-2096.
2. Ashizawa, N., Graf, K., Do, YS, Nunohiro, T., Giachelli, CM, Meehan, WP, Tuan, TL and Hsueh, WA. (1996) Osteopontin is produced by rat cardiac fibroblasts and mediates A(II)-induced DNA synthesis and collagen gel contraction. Journal of Clinical Investigation, 98, pp. 2218-2227.
3. Brilla, CG, Pick, R., Tan, LB, Janicki, JS and Weber, KT. (1990) Remodeling of the rat right and left ventricles in experimental hypertension. Circulation Research, 67, pp. 1355-1364.
4. Brilla, CG, Matsubara, LS and Weber, KT. (1993) Antifibrotic effects of spironolactone in preventing myocardial fibrosis in systemic arterial hypertension. American Journal of Cardiology, 71, pp. 12A-16A.
5. Bristow, MR. (1984) The adrenergic nervous system in heart failure. New England Journal of Medicine, 311, pp. 850-851.
6. Cavallero, S., Gonzalez, GE, Puyo, AM, Roson, MI, Perez, S., Morales, C., Hertig, CM, Gelpi, RJ and Fernandez, BE Atrial natriuretic peptide behaviour and myocyte hypertrophic profile in combined pressure and volume-induced cardiac hypertrophy. J Hypertension, 25, pp. 1940-1950.
7. Cohn, JN. (1995) Structural basis for heart failure: Ventricular remodeling and its pharmacological inhibition. Circulation, 91, pp. 2504-2507.
8. Collins, AR, Schnee, J., Wang, W., Kim, S., Fishbein, MC, Bruemmer, D., Law, RE, Nicholas, S., Ross, RS and Hsueh, WA. (2004) Osteopontin modulates angiotensin II-induced fibrosis in the intact murine heart. Journal of the American Collage of Cardiology, 43, pp. 1698-1705.
9. Delyani, JA, Rocha, R., Cook, CS, Tobert, DS, Levin, S., Roniker, B., Workman, DL, Sing, YL and Whelihan, B. (2001) Eplerenone: A selective aldosterone receptor antagonist (SARA). Cardiovascular Drug Reviews, 19, pp. 185-200.
10. De Mello, WC. (2006) Beneficial effect of eplerenone on cardiac remodelling and electrical properties of the failing heart. Journal of the Renin-Angiotensin-Aldosterone System, 7, pp. 40-46.
11. Dibbs, Z., Kurrelmeyer, K., Kalra, D., Seta, Y., Wang, F., Bozkurt, B., Baumgarten, G., Sivasubramanian, N. and Mann, DL. (1999) Cytokines in heart failure: Pathogenetic mechanisms and potential treatment. Proceedings of the Association of American Physicians, 111, pp. 423-428.
12. George, J., Patal, S., Wexler, D., Roth, A., Sheps, D. and Keren, G. (2005) Circulating matrix metalloproteinase-2 but not matrix metalloproteinase-3, matrix metalloproteinase-9, or tissue inhibitor of metalloproteinase-1 predicts outcome in patients with congestive heart failure. American Heart Journal, 150, pp. 484-487.
13. Gomez, DE, Alonso, DF, Yoshiji, H. and Thorgeirsson, UP. (1997) Tissue inhibitors of metalloproteinases: Structure, regulation and biological functions. European Journal of Cell Biology, 74, pp. 111-122.
14. Graf, K., Do, YS, Ashizawa, N., Meehan, WP, Giachelli, CM, Marboe, CC, Fleck, E. and Hsueh, WA. (1997) Myocardial osteopontin expression is associated with left ventricular hypertrophy. Circulation, 96, pp. 3063-3071.
15. Guerra, S., Leri, A., Wang, X., Finato, N., Loreto, C Di, Beltrami, CA, Kajstura, J. and Anversa, P. (1999) Myocyte death in the failing human heart is gender dependent. Circulation Research, 85, pp. 856-866.
16. Kohno, M., Horio, T., Yoshiyama, M. and Takeda, T. (1992) Accelerated secretion of brain natriuretic peptide from the hypertrophied ventricles in experimental malignant hypertension. Hypertension, 19, pp. 206-211.
17. Lal, A., Veinot, JP, Ganten, D. and Leenen, FH. (2005) Prevention of cardiac remodeling after myocardial infarction in transgenic rats deficient in brain angiotensinogen. Journal of Molecular and Cellular Cardiology, 39, pp. 521-529.
18. Matsui, Y., Jia, N., Okamoto, H., Kon, S., Onozuka, H., Akino, M., Liu, L., Morimoto, J., Rittling, SR, Denhardt, DT, Kitabatake, A. and Uede, T. (2004) Role of osteopontin in cardiac fibrosis and remodeling in angiotensin II-induced cardiac hypertrophy. Hypertension, 43, pp. 1195-1201.
19. Mi, Z., Guo, H., Wai, PY, Gao, C. and Kuo, PC. (2006) Integrin-linked kinase regulates osteopontin-dependent MMP-2 and uPA expression to convey metastatic function in murine mammary epithelial cancer cells. Carcinogenesis, 27, pp. 1134-1145.
20. Mulatero, P., Milan, A., Williams, TA and Veglio, F. (2006) Mineralocorticoid receptor blockade in the protection of target organ damage. Cardiovascular & Hematological Agents in Medicinal Chemistry, 4, pp. 75-91.
21. Nicoletti, A., Heudes, D., Hinglais, N., Appay, MD, Philippe, M., Sassy-Prigent, C., Bariety, J. and Michel, JB. (1995) Left ventricular fibrosis in renovascular hypertensive rats. Effect of losartan and spironolactone. Hypertension, 26, pp. 101-111.
22. Noji, Y., Shimizu, M., Ino, H., Higashikata, T., Yamaguchi, M., Nohara, A., Horita, T., Shimizu, K., Ito, Y., Matsuda, T., Namura, M. and Mabuchi, H. (2004) Increased circulating matrix metalloproteinase-2 in patients with hypertrophic cardiomyopathy with systolic dysfunction. Circulation Journal, 68, pp. 355-360.
23. Olivetti, G., Abbi, R., Quaini, F., Kajstura, J., Cheng, W., Nitahara, JA, Quaini, E., Loreto, C Di, Beltrami, CA and Krajewski, S. (1997) Apoptosis in the failing human heart. New England Journal of Medicine, 336, pp. 1131-1141.
24. Okamoto, H. (2007) Osteopontin and cardiovascular system. Molecular and Cellular Biochemistry, 300, pp. 1-7.
25. Pitt, B., Zannad, F., Remme, WJ, Cody, R., Castaigne, A., Perez, A., Palensky, J. and Wittes, J. (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. New England Journal of Medicine, 341, pp. 709-717.
26. Polyakova, V., Hein, S., Kostin, S., Ziegelhoeffer, T. and Schaper, J. (2004) Matrix metalloproteinases and their tissue inhibitors in pressure overloaded human myocardium during heart failure progression. Journal of the American College of Cardiology, 44, pp. 1609-1618.
27. Robert, V., Silvestre, JS, Charlemagne, D., Sabri, A., Trouve, P., Wassef, M., Swynghedauw, B. and Delcayre, C. (1995) Biological determinants of aldosterone-induced cardiac fibrosis in rats. Hypertension, 26, pp. 971-978.
28. Rosamond, W., Flegal, K., Friday, G., Furie, K. and Go, A. (2007) Heart Disease and Stroke Statistics-2007 Update: A Report From the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation, 115, pp. 69-171.
29. Schrier, RW. (1990) Body fluid volume regulation in health and disease: a unifying hypothesis. Annals of Internal Medicine, 113, pp. 155-159.
30. Singh, K., Sirokman, G., Communal, C., Robinson, KG, Conrad, CH, Brooks, WW, Bing, OH and Colucci, WS. (1999) Myocardial osteopontin expression coincides with the development of heart failure. Hypertension, 33, pp. 663-670.
31. Spinale, FG. (2002) Matrix metalloproteinases: Regulation and dysregulation in the failing heart. Circulation Research, 90, pp. 520-530.
32. Sun, Y., Ramires, FJ and Weber, KT. (1997) Fibrosis of atria and great vessels in response to angiotensin II or aldosterone infusion. Cardiovascular Research, 35, pp. 138-147.
33. Sundströ;m, J., Evans, JC, Benjamin, EJ, Levy, D., Larson, MG, Sawyer, DB, Siwik, DA, Colucci, WS, Wilson, PW and Vasan, RS. (2004) Relations of plasma total TIMP-1 levels to cardiovascular risk factors and echocardiographic measures: The Framingham heart study. European Heart Journal, 25, pp. 1509-1516.
34. Takeda, Y., Yoneda, T., Demura, M., Miyamori, I. and Mabuchi, H. (2000) Sodium-induced cardiac aldosterone synthesis causes cardiac hypertrophy. Endocrinology, 141, pp. 1901-1904.
35. Weber, KT. (1999) Aldosterone and spironolactone in heart failure. New England Journal of Medicine, 341, pp. 753-755.
36. Xie, Z., Singh, M. and Singh, K. (2004) Osteopontin modulates myocardial hypertrophy in response to chronic pressure overload in mice. Hypertension, 44, pp. 826-831.
37. Xie, Z., Singh, M., Siwik, DA, Joyner, WL and Singh, K. (2003) Osteopontin inhibits interleukin-1beta-stimulated increases in matrix metalloproteinase activity in adult rat cardiac fibroblasts: Role of protein kinase C-zeta. Journal of Biological Chemistry, 278, pp. 48546-48552.
38. Yamazaki, T., Lee, JD, Shimizu, H., Uzui, H. and Ueda, T. (2004) Circulating matrix metalloproteinase-2 is elevated in patients with congestive heart failure. European Journal of Heart Failure, 6, pp. 41-45.
39. Yasue, H., Yoshimura, M., Sumida, H., Kikuta, K., Kugiyama, K., Jougasaki, M., Ogawa, H., Okumura, K., Mukoyama, M. and Nakao, K. (1994) Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation, 90, pp. 195-203.
40. Young, M., Head, G. and Funder, J. (1995) Determinants of cardiac fibrosis in experimental hypermineralocorticoid states. American Journal of Physiology, 269, pp. E657-E662.